Covered recipient · General Payments record
KEVIN PATEL
Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology
General Payments · PY2020–2024
$19,812.24
- Reported across 111 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $1,013.00 | 1 |
| Education | $147.28 | 13 |
| Food and Beverage | $117.84 | 6 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| TG THERAPEUTICS, INC. | $1,013.00 | 1 |
| Amgen Inc. | $151.40 | 14 |
| Genentech USA, Inc. | $60.05 | 2 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $33.36 | 2 |
| GlaxoSmithKline, LLC. | $20.31 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (20)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | $11.41 | 01/02/2024 | Education | Undisputed | 01/23/2026 | 1111672782 | CMS |
| Amgen Inc. | $11.41 | 02/19/2024 | Education | Undisputed | 01/23/2026 | 1111672784 | CMS |
| Amgen Inc. | $13.11 | 03/20/2024 | Education | Undisputed | 01/23/2026 | 1111672786 | CMS |
| Amgen Inc. | $10.52 | 04/02/2024 | Education | Undisputed | 01/23/2026 | 1111672788 | CMS |
| Amgen Inc. | $13.11 | 04/08/2024 | Education | Undisputed | 01/23/2026 | 1111672790 | CMS |
| Amgen Inc. | $4.12 | 05/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111672792 | CMS |
| Amgen Inc. | $10.52 | 05/02/2024 | Education | Undisputed | 01/23/2026 | 1111672794 | CMS |
| Amgen Inc. | $10.52 | 06/18/2024 | Education | Undisputed | 01/23/2026 | 1111672796 | CMS |
| Amgen Inc. | $10.52 | 06/25/2024 | Education | Undisputed | 01/23/2026 | 1111672798 | CMS |
| Amgen Inc. | $10.52 | 07/24/2024 | Education | Undisputed | 01/23/2026 | 1111672802 | CMS |
| Amgen Inc. | $11.41 | 07/29/2024 | Education | Undisputed | 01/23/2026 | 1111672800 | CMS |
| Amgen Inc. | $11.41 | 08/30/2024 | Education | Undisputed | 01/23/2026 | 1111672804 | CMS |
| Amgen Inc. | $11.41 | 09/12/2024 | Education | Undisputed | 01/23/2026 | 1111672806 | CMS |
| Amgen Inc. | $11.41 | 09/24/2024 | Education | Undisputed | 01/23/2026 | 1111672808 | CMS |
| Genentech USA, Inc. | $29.17 | 09/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133048068 | CMS |
| Genentech USA, Inc. | $30.88 | 10/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133048073 | CMS |
| GlaxoSmithKline, LLC. | $20.31 | 11/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116312153 | CMS |
| Novartis Pharmaceuticals Corporation | $18.67 | 09/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1087170955 | CMS |
| Novartis Pharmaceuticals Corporation | $14.69 | 10/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1087170963 | CMS |
| TG Therapeutics, Inc. | $1,013.00 | 12/13/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1136887654 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2020, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.